Peter H.
- Country
- Germany
- Department
- Dermatologie
Research Overview
- Efficacy and Safety Evaluation of Bimekizumab Versus Ustekinumab in Pediatric Patients with Moderate to Severe Plaque Psoriasis
- Evaluation of Baricitinib Pharmacokinetics, Efficacy, and Safety in Pediatric Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 3 Randomized Controlled Trial
- I4V-MC-JAIO: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Baricitinib in Children from 6 Years to less than 18 Years of Age with Alopecia Areata
Data & Insights
Has run more than one trial at 46 of 142 partner sites.
Specializations
Pediatric Dermatology
This investigator specializes in treating complex dermatological conditions in children and adolescents, with particular focus on moderate to severe plaque psoriasis and innovative therapeutic approaches using novel treatments like deucravacitinib and bimekizumab.
- Pediatric psoriasis management
- Novel biologic therapies
- Age-specific treatment protocols
Rare Skin Disorders
The investigator demonstrates expertise in treating rare dermatological conditions, including Netherton syndrome and alopecia areata. Their work involves evaluating targeted therapies such as spesolimab and baricitinib for these challenging conditions.
- Genetic skin disorders
- Autoimmune skin conditions
- Advanced therapeutic solutions
Inflammatory Skin Diseases
The investigator focuses on treating inflammatory skin conditions, particularly atopic dermatitis in pediatric populations. Their expertise extends to evaluating JAK inhibitors and other innovative treatment approaches for chronic inflammatory skin disorders.
- Pediatric atopic dermatitis
- Immunomodulatory therapies
- Long-term disease management
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.